Medicortex International AB (publ) (NGM:MEDFIN)

Market Cap	26.25M +191.1%
Revenue (ttm)	2.20M -59.9%
Net Income	1.83M
EPS	0.58
Shares Out	23.33M
PE Ratio	2.08
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,125
Open	n/a
Previous Close	1.200
Day's Range	n/a
52-Week Range	1.095 - 4.200
Beta	1.01
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About NGM:MEDFIN

Medicortex International AB (publ), through its subsidiary, Medicortex Finland Oyj, develops diagnostic tests based on biomarkers for traumatic brain injury, concussions, and other neurodegenerative conditions. It develops ProbTBI, a diagnostic test for urine; and IndicateTBI, a diagnostic test for saliva. It operates in Finland and Sweden. The company was formerly known as Nosium AB (publ) and changed its name to Medicortex International AB (publ) in July 2026. Medicortex International AB (publ) was founded in 2014 and is based in Stockholm, S...

• Industry: Soap, Detergents, And Cleaning Preparations; Perfumes, Cosmetics, and Other Toilet Preparations
• Founded: 2014
• Employees: 3
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: MEDFIN

Financial Performance

In 2025, NGM:MEDFIN's revenue was 4.92 million, a decrease of -31.21% compared to the previous year's 7.15 million. Losses were -9.56 million, -71.15% less than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 27, 2026

Data Sources Report a data error